Ligand Pharmaceuticals (LGND) Set to Announce Earnings on Thursday

Key Points

• Ligand Pharmaceuticals is scheduled to report Q3 2026 earnings before the market opens Thursday, October 29. Analysts expect $2.33 in EPS on $77.0 million in revenue, while the company’s full-year EPS guidance is $9.00–$9.50.
• In its prior quarter, Ligand reported $2.37 EPS and $63.69 million in revenue, exceeding consensus estimates; revenue increased 33.8% year over year.
• Wall Street remains bullish, with all 10 tracked analysts rating the stock a Buy and a consensus price target of $337.89. Shares recently traded at $314.78, near their 52-week high of $326.63, while insiders have sold approximately $16.1 million of stock over the past 90 days.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $2.33 per share and revenue of $77.00 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Investors may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.97 by $0.40. The firm had revenue of $63.69 million for the quarter, compared to the consensus estimate of $61.30 million. Ligand Pharmaceuticals had a net margin of 67.88% and a return on equity of 20.06%. The company's quarterly revenue was up 33.8% on a year-over-year basis. During the same period last year, the firm earned $1.60 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $5.25 EPS for the current fiscal year and $8.35 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock opened at $314.78 on Thursday. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 2.45 and a beta of 1.14. The company's 50 day moving average is $293.12 and its 200 day moving average is $271.15. The company has a quick ratio of 30.96, a current ratio of 31.18 and a debt-to-equity ratio of 1.16. Ligand Pharmaceuticals has a 52-week low of $175.89 and a 52-week high of $326.63.

Insider Activity

In other news, insider Andrew Reardon sold 5,000 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $304.07, for a total value of $1,520,350.00. Following the sale, the insider directly owned 31,854 shares in the company, valued at approximately $9,685,845.78. This trade represents a 13.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Octavio Espinoza sold 31,641 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $292.06, for a total transaction of $9,241,070.46. Following the completion of the transaction, the chief financial officer directly owned 27,696 shares in the company, valued at approximately $8,088,893.76. The trade was a 53.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 54,979 shares of company stock valued at $16,068,898 over the last 90 days. 5.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LGND has been the subject of a number of analyst reports. Royal Bank Of Canada upped their target price on Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Stifel Nicolaus lifted their price target on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Bank of America lifted their price target on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a "buy" rating in a report on Thursday, July 9th. Citigroup boosted their price target on Ligand Pharmaceuticals from $390.00 to $397.00 and gave the stock a "buy" rating in a research report on Wednesday, September 23rd. Finally, Leerink Partners initiated coverage on Ligand Pharmaceuticals in a research report on Friday, August 14th. They issued an "outperform" rating and a $330.00 price target for the company. Ten analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $337.89.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated NASDAQ: LGND is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.

The company's principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.